South Korea
· Delayed Price · Currency is KRW WITHUS PHARMACEUTICAL Co.,LTD. Statistics
Total Valuation
WITHUS PHARMACEUTICAL Co.,LTD. has a market cap or net worth of KRW 94.00 billion. The enterprise value is 106.83 billion.
| Market Cap | 94.00B |
| Enterprise Value | 106.83B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
WITHUS PHARMACEUTICAL Co.,LTD. has 13.20 million shares outstanding. The number of shares has increased by 0.20% in one year.
| Shares Outstanding | 13.20M |
| Shares Change (YoY) | +0.20% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 52.94% |
| Owned by Institutions (%) | n/a |
| Float | 6.10M |
Valuation Ratios
The trailing PE ratio is 12.29.
| PE Ratio | 12.29 |
| Forward PE | n/a |
| PS Ratio | 0.96 |
| PB Ratio | 1.04 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.81, with an EV/FCF ratio of -14.72.
| EV / Earnings | 13.96 |
| EV / Sales | 1.09 |
| EV / EBITDA | 8.81 |
| EV / EBIT | 12.36 |
| EV / FCF | -14.72 |
Financial Position
The company has a current ratio of 1.80, with a Debt / Equity ratio of 0.24.
| Current Ratio | 1.80 |
| Quick Ratio | 1.13 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | 1.77 |
| Debt / FCF | -2.96 |
| Interest Coverage | 11.02 |
Financial Efficiency
Return on equity (ROE) is 8.70% and return on invested capital (ROIC) is 5.01%.
| Return on Equity (ROE) | 8.70% |
| Return on Assets (ROA) | 4.31% |
| Return on Capital (ROIC) | 5.01% |
| Revenue Per Employee | 812.18M |
| Profits Per Employee | 63.24M |
| Employee Count | 121 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 2.67 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.06% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -35.06% |
| 50-Day Moving Average | 7,654.20 |
| 200-Day Moving Average | 8,218.60 |
| Relative Strength Index (RSI) | 44.72 |
| Average Volume (20 Days) | 29,644 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, WITHUS PHARMACEUTICAL Co.,LTD. had revenue of KRW 98.27 billion and earned 7.65 billion in profits. Earnings per share was 579.49.
| Revenue | 98.27B |
| Gross Profit | 62.15B |
| Operating Income | 8.64B |
| Pretax Income | 8.65B |
| Net Income | 7.65B |
| EBITDA | 12.12B |
| EBIT | 8.64B |
| Earnings Per Share (EPS) | 579.49 |
Balance Sheet
The company has 8.65 billion in cash and 21.48 billion in debt, giving a net cash position of -12.83 billion or -971.72 per share.
| Cash & Cash Equivalents | 8.65B |
| Total Debt | 21.48B |
| Net Cash | -12.83B |
| Net Cash Per Share | -971.72 |
| Equity (Book Value) | 90.72B |
| Book Value Per Share | 6,872.96 |
| Working Capital | 25.46B |
Cash Flow
In the last 12 months, operating cash flow was -1.98 billion and capital expenditures -5.28 billion, giving a free cash flow of -7.26 billion.
| Operating Cash Flow | -1.98B |
| Capital Expenditures | -5.28B |
| Free Cash Flow | -7.26B |
| FCF Per Share | -549.65 |
Margins
Gross margin is 63.24%, with operating and profit margins of 8.79% and 7.79%.
| Gross Margin | 63.24% |
| Operating Margin | 8.79% |
| Pretax Margin | 8.80% |
| Profit Margin | 7.79% |
| EBITDA Margin | 12.33% |
| EBIT Margin | 8.79% |
| FCF Margin | -7.38% |
Dividends & Yields
WITHUS PHARMACEUTICAL Co.,LTD. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 17.24% |
| Buyback Yield | -0.20% |
| Shareholder Yield | -0.20% |
| Earnings Yield | 8.14% |
| FCF Yield | -7.72% |
Stock Splits
The last stock split was on June 11, 2021. It was a forward split with a ratio of 1.5.
| Last Split Date | Jun 11, 2021 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
WITHUS PHARMACEUTICAL Co.,LTD. has an Altman Z-Score of 3.68.
| Altman Z-Score | 3.68 |
| Piotroski F-Score | n/a |